Edwards Lifesciences (EW) is a publicly traded Healthcare sector company. As of May 20, 2026, EW trades at $82.46 with a market cap of $47.44B and a P/E ratio of 43.66. EW moved +0.84% today. Year to date, EW is -1.43%; over the trailing twelve months it is +6.60%. Its 52-week range spans $64.01 to $87.89. Analyst consensus is strong buy with an average price target of $97.80. Rallies surfaces EW's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
EW financials on Rallies include revenue, net income, EPS, valuation metrics, market cap, price history, and balance sheet context. EW recently traded at $82.46. Market cap is $47.44B. P/E ratio is 43.66. Revenue is $6.30B.
| Metric | Value |
|---|---|
| Price | $82.46 |
| Market Cap | $47.44B |
| P/E Ratio | 43.66 |
| EPS | $1.89 |
| Dividend Yield | 0.00% |
| 52-Week High | $87.89 |
| 52-Week Low | $64.01 |
| Volume | 3.24M |
| Avg Volume | 0 |
| Revenue (TTM) | $6.30B |
| Net Income | $1.09B |
| Gross Margin | 77.87% |
| Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $6.07B | $1.07B | $1.84 |
| 2023 | $6.00B | $1.40B | $2.31 |
| 2022 | $5.38B | $1.52B | $2.46 |
| 2021 | $5.23B | $1.50B | $2.41 |
17 analysts cover EW: 0 strong buy, 14 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $97.80.